Trial Profile
Open-Label, randomized, partially balanced, incomplete block design study to evaluate the hormone exposure from commercial ORTHO EVRA [ethinylestradiol/norelgestromin]
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Ethinylestradiol/norelgestromin (Primary)
- Indications Pregnancy
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 24 Aug 2006 New trial record.